By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into an agreement to sell $51.6 million worth of its common stock to unnamed investors in a private placement.

The San Diego-based molecular diagnostics firm said that it will sell 12,435,000 shares of its common stock at a price of $4.15 per share to certain investors. It expects to close the financing on or around May 17.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.